VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

 

Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].

                                           

 

25th June 2015 - News release

INHALED L-DOPA - PARKINSON'S DISEASE CLINICAL TRIAL RESULTS

 CLICK HERE FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE

CVT-301 is the name of an inhaled version of L-dopa presently being developed for the treatment of Parkinson's Disease. Clinical trial results demonstrated improved efficacy that was apparent in only 10 minutes. CVT-301 uses the ARCUS inhalation technology, which delivers a reliable and consistent drug dose with a compact, breath actuated inhaler. The inhaled version of L-dopa would be used alongside the use of oral L-dopa.

The clinical trial showed that patients experiencing an OFF episode, treated with either 35mg or 50mg CVT-301, had significantly greater improvements in motor function than patients treated with inhaled placebo. The difference in improvement was already apparent 10 minutes after dosing and was durable for at least an hour, the longest time point at which patients were measured. This enables fast working L-dopa unlike what has ever been seen before.

Both doses of CVT-301 were well tolerated, with no increase relative to placebo in troublesome or non-troublesome dyskinesias during ON periods. The most common adverse events were dizziness, headache and cough. There were no adverse events on cardiovascular or lung function. For more information go to Acorda

Based on the results of the Phase 2b clinical trial, Acorda has initiated a Phase 3 clinical trial in order to assess efficacy that is expected to enroll approximately 345 participants who will take either 50mg, 35mg, or placebo, just as were used in the Phase 2b clinical trial. For more news go to Parkinson's Disease News

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.


PARKINSON'S DISEASE BOOKS from Amazon


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
©2006-2015  Viartis
 
2015-07-19 18:26:39
 
[email protected]